In this study, we found that HAT1 overexpression in pancreatic cancer cells promoted gemcitabine resistance and that HAT1 silencing restored sensitivity to the antitumor effects of gemcitabine. The gene discussed is HAT1; the disease is pancreatic neoplasm.